Direkt zum Inhalt
Merck

Deciphering the proteomic signature of human endometrial receptivity.

Human reproduction (Oxford, England) (2014-08-12)
Tamara Garrido-Gómez, Alicia Quiñonero, Oreto Antúnez, Patricia Díaz-Gimeno, Jose Bellver, Carlos Simón, Francisco Domínguez
ZUSAMMENFASSUNG

Are there any proteomic differences between receptive (R) and non-receptive (NR) endometrial receptivity array (ERA)-diagnosed endometria obtained on the same day of a hormonal replacement therapy (HRT) treatment cycle? There is a different proteomic signature between R and NR ERA-diagnosed endometrium obtained on the same day of HRT cycles. The human endometrial transcriptome has been extensively investigated in the last decade resulting in the development of a new diagnostic test based on the transcriptomic signature of the window of implantation (WOI). Much less is known about the proteomics derived from the transcripts present during the WOI. This study was a basic proteomic analysis of human endometrial biopsies taken from twelve IVF patients. Human endometrial biopsies were collected during HRT cycles after 5 days of progesterone (P) administration, and diagnosed as receptive (R; n = 6) or non-receptive (NR; n = 6) by the ERA test. Endometrial proteins were extracted, labelled and separated using differential in-gel electrophoresis (DIGE). Proteins were identified using mass spectrometry, followed up by in silico analysis. Validation studies using western blots and immunolocalization were performed for the progesterone receptor membrane component 1 (PGRMC1) and annexin A6 (ANXA6) proteins. DIGE analysis followed by protein identification by MALDI-MS and database searches revealed 24 differentially expressed proteins in R versus NR samples. In silico analysis showed two pathways which were significantly different between R and NR samples. Expression of PGRMC1 and ANXA6 was validated and localized by western blots and immunohistochemistry. These results highlight these proteins as key targets likely to be important in the comprehension of human endometrial receptivity. This was mainly a descriptive study with no functional studies on the proteins found. We also used a low number of human endometrial samples for the DIGE analysis. This study identified the proteomic profile associated with receptive or non-receptive human endometria. Our findings suggest that although histological dating indicates a putative 'receptive' status within the WOI, a different transcriptomic and proteomic profile is observed in these samples. We should move towards using more personalized WOIs, where identification of the correct endometrial receptivity status, and consequently the success of IVF, relies on individual molecular signatures rather than traditional endometrial dating. F.D.'s participation in this work was supported by the Spanish Ministry of Economy and Competitiveness, through the Miguel Servet Programme (CP13/00075) co-founded by FEDER. The project was also supported by a grant from the Spanish Ministry of Economy and Competitiveness, through the FIS Programme (PI12/00450). The authors have no financial/commercial conflicts of interest to declare.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Glycin, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Glycin, suitable for electrophoresis, ≥99%
Sigma-Aldrich
Harnstoff, powder, BioReagent, Molecular Biology, suitable for cell culture
Sigma-Aldrich
N-Hydroxysuccinimid, 98%
Sigma-Aldrich
Harnstoff, ACS reagent, 99.0-100.5%
Sigma-Aldrich
Glycin, BioUltra, Molecular Biology, ≥99.0% (NT)
Sigma-Aldrich
Glycin, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Supelco
Harnstoff, 8 M (after reconstitution with 16 mL high purity water)
Sigma-Aldrich
Harnstoff -Lösung, BioUltra, ~8 M in H2O
Sigma-Aldrich
Progesteron, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Harnstoff, ReagentPlus®, ≥99.5%, pellets
Sigma-Aldrich
Harnstoff, BioUltra, Molecular Biology, 99% (T)
Sigma-Aldrich
Progesteron, ≥99%
Sigma-Aldrich
Harnstoff, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
SAFC
Glycin
Supelco
Glycin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Harnstoff, suitable for electrophoresis
Sigma-Aldrich
Glycin, ACS reagent, ≥98.5%
Sigma-Aldrich
Glycin, BioXtra, ≥99% (titration)
Sigma-Aldrich
Harnstoff, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)
Sigma-Aldrich
Progesteron, meets USP testing specifications
Supelco
Harnstoff, analytical standard
Sigma-Aldrich
Harnstoff, meets USP testing specifications
Sigma-Aldrich
Glycin, 99%, FCC
USP
Harnstoff, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Progesteron, γ-irradiated, BioXtra, suitable for cell culture
Supelco
Progesteron, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Glycin, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Harnstoff, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99%
Sigma-Aldrich
Glycin, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)